

REVISIÓN DE LITERATURA. INFECCIÓN POR EL VIH. SEIMC 2021

Dra. Rosario Palacios

Unidad de Enfermedades Infecciosas, Hospital Virgen de la Victoria de Málaga

1. Overton ET, Richmond G, Rizzardini G, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. *Lancet* 2020; 396: 1994–2005.
2. Kufel WD. Antibody-based strategies in HIV therapy. *International Journal of Antimicrobial Agents* 2020; 56: 106186.
3. Leal L, Fehér C, Richart V, et al. Antiretroviral therapy interruption (ATI) in HIV-1 infected patients participating in therapeutic vaccine trials: surrogate markers of virological response. *Vaccines* 2020, 8, 442; doi:10.3390/vaccines8030442.
4. Lockman S, Brummel SS, Ziembra L, et al. Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial. *Lancet* 2021; 397: 1276–1292.